James Howard Tonsgard to Neurofibromatoses
This is a "connection" page, showing publications James Howard Tonsgard has written about Neurofibromatoses.
Connection Strength
0.729
-
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
Score: 0.231
-
Current Recommendations for Patient-Reported Outcome Measures Assessing Domains of Quality of Life in Neurofibromatosis Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S50-S63.
Score: 0.176
-
Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016 Aug 16; 87(7 Suppl 1):S4-S12.
Score: 0.126
-
Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S6-14.
Score: 0.104
-
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
Score: 0.051
-
Late-onset neurofibromatosis in a liver transplant recipient. Int J Dermatol. 2000 May; 39(5):376-9.
Score: 0.041